Hi Lopez From the SITC 2017 abstracts (O41 on pages 108/109), the BMS trial of its IDO1 & Opdivo combo resulted in 11% Grade 3/4 SAEs and another 2% discontinuation from drug toxicity (including a death) from 216 patients. https://higherlogicdownload.s3.amaz...nual Meeting 2017/SITC_2017_Abstract_Book.pdf So it looks like the IV Cavatak/Keytruda combo has a slightly better safety profile (& more importantly, no toxicity-related deaths !) Cheers
AHK Ark Mines inks 1.5Bt Exploration Target for Sandy Mitchell REE play including NdPr; PFS due in Q4